Gemcitabine plus carboplatin regimen in treatment of advanced non-small cell lung cancer in aged patients

闫霞; 曹官铭; 王导新

您当前的位置：

首页 >

文章列表页 >

Gemcitabine plus carboplatin regimen in treatment of advanced non-small cell lung cancer in aged patients

更新时间：2026-01-09

- Gemcitabine plus carboplatin regimen in treatment of advanced non-small cell lung cancer in aged patients
- Journal of Army Medical University Vol. 29, Issue 19, Pages: 1913-1915(2007)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC： R730.53;R734.2;R979.12
- Published：2007
- 稿件说明：
移动端阅览
闫霞,曹官铭,王导新.吉西他滨联合卡铂治疗老年非小细胞肺癌的临床评价[J].陆军军医大学学报(原第三军医大学学报),2007,29(19):1913-1915.

　YAN Xia,CAO Guan-min,WANG Dao-xin.Gemcitabine plus carboplatin regimen in treatment of advanced non-small cell lung cancer in aged patients[J].J Amry Med Univ (J Third Mil Med Univ),2007,29(19):1913-1915.
闫霞,曹官铭,王导新.吉西他滨联合卡铂治疗老年非小细胞肺癌的临床评价[J].陆军军医大学学报(原第三军医大学学报),2007,29(19):1913-1915. DOI：

　YAN Xia,CAO Guan-min,WANG Dao-xin.Gemcitabine plus carboplatin regimen in treatment of advanced non-small cell lung cancer in aged patients[J].J Amry Med Univ (J Third Mil Med Univ),2007,29(19):1913-1915. DOI：

摘要

目的观察吉西他滨（gemcitabine

GEM）联合卡铂（carboplatin

CBP）在晚期老年非小细胞肺癌临床疗效及毒性反应。方法 60例晚期老年（≥65岁）非小细胞肺癌分成吉西他滨组（A组）和长春瑞滨组（B组），A组：吉西他滨+卡铂（30例），B组：长春瑞滨+顺铂（30例）。吉西他滨1 000 mg/ m

，第1、8天

卡铂300 mg/m

第1天

每3周为1个周期；长春瑞滨25 mg/ m

，第1、8天

顺铂80 mg/m

，第1、3天，每3周为1个周期。结果 60例患者的症状均有不同程度的改善。A组及B组有效率为43.3%及36.7%

两组间无显著性差异(P0.05)。中位生存期（median survival time

MST）、疾病缓解时间（disease median response time

DPT）A组及B组分别为9.2个月、8.9个月及4.4个月、4.2个月。1年生存率A组及B组分别为455%、41.6%。两组间无显著性差异(P0.05)。毒性反应：B组白细胞Ⅲ/Ⅳ度下降发生率和静脉炎的发生率明显高于A组(P0.05)。结论吉西他滨+卡铂与长春瑞滨+顺铂对晚期老年非小细胞肺癌的近期临床疗效相近，MST、DTP、1年生存率均相似，但吉西他滨组耐受性及毒性反应低于长春瑞滨组。吉西他滨联合卡铂方案可作为治疗晚期老年非小细胞肺癌有效的化疗方案。

Abstract

Objective To evaluate and the effects and safety of gemcitabine plus carboplatin (GEM+CBP) regimen and navebine plus cisplatin (NVB+DDP) regimens for aged patients with advanced non-small cell lung cancer (NSCLC). Methods The 60 cases of aged patients with NSCLC

over 65 years old and 35 cases beyond 70

were randomly and equally divided into 2 groups. Group A received 1 000 mg/m

GEM at day 1 and 8

and 300 mg/m

CBP at day 1. Group B underwent the therapy of 25 mg/ m

NVB at day 1 and 8

and 80 mg/m

DDP at day 1 and 3. Both were treated with 3 weeks as a cycle. Results Overall response rate was 43.3% in group A and 36.7% in group B without significant difference. The median survival time (MST) and disease median response time(DPT) was 9.2 and 4.4 months in A group

and 8.9 and 4.2 months in B group. MST

DPT and one year survival rate were similar in 2 groups. Toxicities: WHO grade Ⅲ/Ⅳ leukopenia occurred in B group was higher than that in A group. The frequence of phlebitis was significantly higher in group B than group A (P0.05). Conclusion There are similar outcomes in the overall response rates

MST

DRT and one year survival rate in 2 groups

but GEM+CBP regimen has a better tolerability and lower toxicities. GEM+CBP regimen is a better chemotherapeutic regimen for aged NSCLC patients.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Integrative model combining deep learning, clinical and radiomic features enhances EGFR mutation prediction in non-small cell lung cancer

Preparation of doxorubicin-loaded polyphyllin H liposomes and synergistic anti-tumor activity against non-small cell lung cancer in vitro

Development of a postoperative recurrence prediction model for stage Ⅰ non-small cell lung cancer patients using multimodal data based on machine learning

Progress and prospect of epidermal growth factor receptor tyrosine kinase inhibitor in treatment of non-small cell lung cancer

Correlation of serum tumor markers and incidence of driver gene mutations in non-small cell lung cancer

Related Author

YANG Taotao

CHEN Wei

CHEN Cancan

YAN Wanying

WANG Dawei

XIONG Kunlin

SUN Zhiyuan

WANG Xianqi

Related Institution

Department of Diagnostic Radiology， Eastern Theatre General Hospital

Department of Radiology， Daping Hospital， Army Medical University

Department of Radiology，First Affiliated Hospital， Army Medical University （Third Military Medical University）

Infervision Medical Technology Co.， Ltd

Department of Medical Service,No. Hospital of Joint Logistics Support Force

⁰